Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

Shareholder links

Our website ranking of EPN: rating 2
(2 out of 5)



Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000THC4
Address: 20 Grose Street North Parramatta NSW 2151
Tel:  02 8839 3000Fax: 02 8839 3055

Date first listed: 04/05/2017

Sector: Pharmaceuticals Biotechnology & Life Sciences 
Activities: THC Global operates under a Farm to Pharma model and is currently delivering high quality medicinal cannabis products to Australian patients through existing access schemes. Having secured both a significant growing capacity over two grow sites, and

News & Events

Expand this box to read and print

At the adjourned second meeting of the Company's creditors held on 31 May 2024 pursuant to section 439A of the Corporations Act, the creditors of the Company resolved, inter alia, that the Company execute a deed of company arrangement. In this regard, at the adjourned second meeting of the Company's creditors: two competing deeds of company arrangement were propounded by, on the one hand, Messrs Xiao (Josh) Cui and Stuart Cameron and, on the other hand, Messrs Alan Beasley and Peter Giannopoulos; and the Company's creditors resolved, inter alia, that the Company execute the deed of company arrangement propounded by Messrs Beasley and Giannopoulos. The creditors in Pharma and Clinics also passed resolutions to execute deeds of company arrangement proposed by Messrs Beasley and Giannopoulos, which proposals were interdependent. The Voluntary Administrators are currently in the process of preparing the relevant documents to give effect to the DOCA, with a view to executing same on or before 24 June 2024. Following the execution of the DOCA (on or before 24 June 2024), control and stewardship of the Company will revert to the Company's then directors. Thereafter, the Company's then directors will be responsible for seeking to have the suspension of the Company's shares lifted.


The company releases a report to shareholders regarding the following: voluntary administrator appointments, the EGMs that did not push through, shareholder communications and the extension of convening periods for second meetings of creditors and investigations.


On 17 January 2024, the Voluntary Administrators applied to the Federal Court of Australia seeking orders, pursuant to section 439A(6) of the Corporations Act, to extend the convening period to 20 March 2024. This has been granted.


The Extraordinary General Meetings that will be convened for Friday, 22 December 2023 at 9:00am and 19 January 2024 at 10:00am have been cancelled.


The securities of Epsilon Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.3. The securities will remain suspended until ASX is satisfied with EPN's ongoing compliance with the Listing Rules.


Ian James Purchas and Hugh Armenis of SV Partners were appointed as Joint and Several Administrators.


The suspension of trading in the securities of Epsilon Healthcare Limited will be lifted immediately, following the release by EPN of an announcement regarding a partnership agreement with The Valens Company Inc.


The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a Binding Heads of Agreement for a long term exclusive partnership with Epsilon, for access to Epsilon's GMP Manufacturing Facility in Southport, Queensland (the Southport Facility). Epsilon's Southport Facility is the largest cannabis extraction facility in the Southern Hemisphere with TGA and EU GMP capability. Marks the first GMP manufactured products to be sold through Valens in Australia and provides Valens with the capability to deliver GMP grade products to Latin America, Europe, UK, and Asia-Pacific. Valens to fund all operational and capital expenditure of the Southport Facility in return for preferential access for up to 85% of the operational capacity of the Southport Facility over the next five years, with options to extend for a further six years. Valens to provide operational and management consultancy at the Southport Facility to bring their industry leading intellectual property, technology and team to the Southport Facility taking advantage of Epsilon's GMP Manufacturing capability. Valens will utilise the Epsilon Southport Facility for all production of medicinal cannabis products for sale in Australian or New Zealand, including through its distribution relationship with Cannvalate. First products manufactured under the partnership expected to be delivered in the coming weeks. Epsilon to acquire AlternaMed Pty Ltd from Cannvalate, including its portfolio of provisional patent applications for three novel cannabinoid therapeutic clinical assets with potential for Schedule 3 medicine development and access to a Sigma Pharmaceuticals storage facility controlled by Cannvalate.


The securities of Epsilon Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of EPN, pending the release of an announcement regarding the execution of binding agreements to secure a long term corporate partnership.


name changed from THC Global Group Limited



Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    28/09/2023Alan Beasley50,000$0.031$1,563
    22/09/2023Alan Beasley2,543,822$0.027$67,434
    12/09/2023Alan Beasley1,931,156$0.024$47,200
    30/06/2023Alan Beasley2,675,022$0.021$54,984
    07/09/2020Gary Radcliff44,900$0.240$10,776

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Alan BeasleyDeputy Chairman, Non Exec Director04/05/2017
    Daniel SangheraInterim CEO21/11/2023
    Mark AudetCFO, Company Secretary30/11/2022
    Zoe HutchingsDirector11/06/2024
    Peter GiannopoulosDirector23/05/2023
    Marcelo MoraCompany Secretary

    Date of first appointment, title may have changed.

    SPECIAL NOTE: During May 2024 we are working to remove duplications in the Company Secretary role.

    Directors & Executives (former)

    Josh CuiExecutive Chairman28/10/202211/06/2024
    Stuart CameronNon Exec Director27/10/202211/06/2024
    John FewNon Exec Director30/11/202313/02/2024
    Wilson MinDirector15/12/202313/02/2024
    Sonny DiduguCOO02/09/202031/12/2022
    Simon RoweNon Exec Director02/08/202103/11/2022
    Steven XuNon Exec Chairman12/01/201801/11/2022
    Nicholas MarshallCFO18/06/202128/10/2022
    Patrick XuDirector03/06/202221/09/2022
    Rob JennyExecutive Director02/08/202107/08/2022
    Jarrod WhiteInterim CEO16/08/201721/07/2022
    Lou CattelanDirector15/03/201829/07/2021
    Mark FortugnoCFO15/01/201918/06/2021
    Gary RadcliffNon Exec Director15/03/201805/03/2021
    Kenneth CharterisCEO11/07/201802/09/2020
    Ian MuttonChairman04/05/201715/03/2018
    Mary VerschuerNon Exec Director04/05/201715/03/2018
    Hamish MacdonaldNon Exec Director04/05/201715/03/2018
    Peter WallaceNon Exec Director04/05/201715/03/2018
    David RadfordCEO19/10/201714/03/2018
    John HallExecutive Director04/05/201719/10/2017

    Date of first appointment, title may have changed.